The REACT Study
Research type
Research Study
Full title
A Prospective Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Events – Assessed by a CMV–specific T SPOT Assay
IRAS ID
185936
Contact name
Sharon Lynch
Contact email
Sponsor organisation
Oxford Immunotec, Inc.
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 2 months, 25 days
Research summary
Reactivation of cytomegalovirus (CMV) subsequent to allogeneic HSCT is a significant and frequent complication in patients who are seropositive for CMV. Reduction of CMV-specific immunity, as may occur in immunosuppressed transplant recipients, is associated with increased risks of recurrent or persistent CMV reactivation and CMV infection. The most important opportunistic organism in stem cell transplantation is cytomegalovirus (CMV). Approximately 75% of recipients are at risk of CMV infection post transplantation because of prior infection in themselves or their donor.
In the current era of immunosuppression, improvements in transplant outcome are perhaps most likely through stratification of individuals’ risk of CMV disease and, or rejection. This could allow immunosuppression and antiviral prophylaxis to be optimized.
The REACT study is the UK arm of an international prospective, observational, study of stem cell transplant recipients.REC name
London - Bloomsbury Research Ethics Committee
REC reference
15/LO/1817
Date of REC Opinion
11 Apr 2016
REC opinion
Further Information Favourable Opinion